CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 14 enrolled
Drug / intervention
Zanamivirdrug
Likely dose
Zanamivir 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04867707
NCT04867707Phase 2Completed
CompareCT.gov

Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes

University of Missouri-Columbia·interventional·Posted Apr 30, 2021·Updated Apr 25, 2025

In Brief

A Phase 2 clinical trial evaluating Zanamivir for Diabetes Mellitus, Type 2. Completed, enrolled 14 participants across 1 site.

Detailed Summary

The objective is to determine if neuraminidase inhibition with zanamivir is efficacious as a therapeutic strategy to restore endothelial function in T2D patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedApr 30, 2021
Enrollment StartJul 14, 2021
Primary CompletionOct 18, 2024
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 5.2 years ago

Interventions

Zanamivirdrug

5 days of treatment with 10mg zanamivir inhaler BID